NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Descending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
10019-0989-01 | 10019-0989 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 16, 1959 | In Use | |
10019-0990-01 | 10019-0990 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 16, 1959 | In Use | |
16714-0857-01 | 16714-0857 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 8, 2019 | In Use | |
16714-0858-01 | 16714-0858 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 8, 2019 | In Use | |
16714-0859-01 | 16714-0859 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan. 8, 2019 | In Use | |
21695-0111-00 | 21695-0111 | Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 15, 1990 | In Use | |
21695-0111-30 | 21695-0111 | Methotrexate sodium | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Oct. 15, 1990 | In Use | |
24535-0831-01 | 24535-0831 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Aug. 20, 2017 | In Use | |
71335-1926-01 | 71335-1926 | Prednisone | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 11, 2021 | In Use | |
71335-1926-02 | 71335-1926 | Prednisone | PREDNISONE | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 11, 2021 | In Use | |
00078-1091-20 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1091-94 | 00078-1091 | asciminib | SCEMBLIX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-20 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
00078-1098-94 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct. 29, 2021 | In Use | |
63020-0040-12 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sept. 15, 2021 | In Use | |
24658-0702-01 | 24658-0702 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0702-05 | 24658-0702 | ESTRADIOL | ESTRADIOL | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0703-01 | 24658-0703 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0703-05 | 24658-0703 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0704-01 | 24658-0704 | ESTRADIOL | ESTRADIOL | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0704-05 | 24658-0704 | ESTRADIOL | ESTRADIOL | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
24658-0704-90 | 24658-0704 | ESTRADIOL | ESTRADIOL | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 10, 2021 | In Use | ||
00009-0051-01 | 00009-0051 | medroxyprogesterone acetate | Provera | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | July 20, 2020 | In Use |
Found 10,000 results in 3 milliseconds — Export these results